About moonlake immunotherapeutics - MLTX
Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.
MLTX At a Glance
MoonLake Immunotherapeutics
Dorfstrasse 29
Zug, Zug 6300
| Phone | 41-41-510-80-22 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -227,318,000.00 | |
| Sector | Health Technology | Employees | 130 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
MLTX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 3.09 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.194 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.142 |
MLTX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,748,600.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
MLTX Liquidity
| Current Ratio | 9.272 |
| Quick Ratio | 9.272 |
| Cash Ratio | 8.663 |
MLTX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -50.383 |
| Return on Equity | -60.513 |
| Return on Total Capital | -59.791 |
| Return on Invested Capital | -54.958 |
MLTX Capital Structure
| Total Debt to Total Equity | 24.865 |
| Total Debt to Total Capital | 19.913 |
| Total Debt to Total Assets | 17.837 |
| Long-Term Debt to Equity | 24.459 |
| Long-Term Debt to Total Capital | 19.589 |